CHICAGO, June  17, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (&#34;Cosmos Health&#34; or the &#34;Company&#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its entry into the

COSM

Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States

Cosmos Health Expands into Global Skincare, Potential Margin-Driven Growth

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CHICAGO, June  17, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (&amp;#34;Cosmos Health&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its entry into the</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cosmos Health announced its entry into the global beauty and personal care market with a premium collagen-based skincare line. US direct-to-consumer sales are already live, with plans to scale globally through a multi-brand strategy. The initiative aims to diversify into higher-margin categories and capitalize on a large, growing skincare market.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Cosmos Health launches premium collagen skincare in global beauty market. US sales underway.</li><li>Diversification targets higher-margin, high-growth categories with a multi-brand plan.</li><li>Global skincare market valued about $163B in 2026; growth to $203B by 2033.</li><li>CEO says beauty entry aligns with growth; sales already underway.</li><li>Premium skincare with science-backed formulations could lift margins.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cosmos Health Inc. (COSM)</strong>: Initiating a premium collagen skincare line in the global beauty market; US sales already underway.</li><li><strong>ZipDoctor, Inc. (ZIPDO)</strong>: Cosmos Health&#039;s telehealth arm; potential cross-sell opportunities with new skincare offerings.</li><li><strong>Cana Laboratories S.A. (CANALABS)</strong>: EU GMP-certified manufacturing backbone; supports new skincare product line and broader portfolio.</li><li><strong>Sky Premium Life (SKYPREM)</strong>: Cosmos Health brand portfolio component; potential brand-driven growth with skincare expansion.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article reports Cosmos Health expanding into a higher-margin, growth-oriented skincare category, illustrating strategic diversification beyond core healthcare products and signaling potential valuation upside if the new line scales globally.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>US skincare sales are live for over a month, signaling near-term revenue potential.</li><li>Global skincare market size and growth provide a favorable backdrop for COSM&#039;s expansion.</li><li>Shift to higher-margin, faster-growing product categories could support margin expansion.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Cosmos Health Inc. trades on NASDAQ as COSM.</li><li>US skincare sales have been live for over one month as of June 17, 2026.</li><li>Global skincare market valued at about $163B in 2026, projected to $203B by 2033 (Grand View Research).</li><li>Cosmos Health is a diversified, vertically integrated healthcare group with operations in Greece and the UK, and GMP/EMA-certified manufacturing via Cana Laboratories S.A.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish: COSM should re-rate on near-term skincare revenue potential and longer-term margin uplift within 6–12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>CHICAGO, June  17, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rPkt0V2ztodbLJCTuqW2bsYRHLcFztzNJaSOU6uSBf6rhULpVb31-YT4zpbHnGXH3XCmrwAItYyFo1s0qJWIllQvRM_0Tc_jmPpoxHhnOZU=" rel="nofollow" target="_blank"><strong><u>Cosmos Health Inc.</u></strong></a><strong> (&#34;Cosmos Health&#34; or the "Company")</strong><a href="https://www.globenewswire.com/Tracker?data=8fsa1ImecqCLdXVtssJ4CTirrWzIJYC6DtoKx3QbEXquAVXFsIltdCO901UrvKLAtQzPL77qT1WiyrxkgUMtUr_D3xBgzoRULa6SL4y4z3U=" rel="nofollow" target="_blank"><strong><u> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</u></strong></a>, a diversified, vertically integrated global healthcare group, today announced its entry into the global beauty and personal care market.</p>  <p>Sales of a new skincare brand — a premium, Korean-developed collagen-based skincare line — have already commenced in the United States and have been live for over a month.</p>  <p>The brand is being introduced through a direct-to-consumer model, beginning in the U.S. with a vision to scale globally. Cosmos Health plans to roll out a series of products, pursuing a multi-brand strategy that extends the Company&#39;s portfolio well beyond core healthcare categories and deepens its presence in the high-growth skincare category.</p>  <p>The launch marks a key step in Cosmos Health&#39;s diversification toward higher-margin products and faster-growing, more lucrative end markets. The global skincare products market was valued at approximately $163 billion in 2026 and is projected to reach roughly $203 billion by 2033, according to <a href="https://www.globenewswire.com/Tracker?data=77K5wGYTYskKW_z6ZGY03GtK9MmISHHZm8pHuqJsDfLX5Y9vMeV3VDGLAivPACmP92tELCGHLkJaue1vfSVccXhNGvCdxI8G1RQm9Ua5y6zucSdNg04IwBNsrTM41AVi8B3ZmEyGboXmZpIBJ9OyzRYYruVfY1TFkNTtUIXgv_o=" rel="nofollow" target="_blank"><u>Grand View Research</u></a>, with premium skincare among the fastest-growing segments amid rising consumer demand for science-backed formulations.</p>  <p><strong>Greg Siokas, CEO of Cosmos Health, stated: </strong>&#34;Entering the global beauty market is a natural extension of our strategy to diversify into higher-margin, high-growth categories. With sales already underway in the United States, a direct-to-consumer model built for global scale, and a multi-brand portfolio of products planned, we believe this new chapter can become a meaningful contributor to our growth."</p>  <p align="justify"><strong>About Cosmos Health Inc.<br></br></strong>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life&#xAE;, Mediterranation&#xAE;, bio-bebe&#xAE;, C-Sept&#xAE; and C-Scrub&#xAE;. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at<a href="https://www.globenewswire.com/Tracker?data=m_tSLsfiv_LmGcZk6TMqueGNwuhQHXbk6TgjbJFyIOnmmPtS0da4nFdJT96oG0c0-Hhu2Q1mafkdtX1H0DUghrzEJXbwz6xy5ROg_Mo1Br6TR8aoLs2rR4yZrbsxqCdd" rel="nofollow" target="_blank"> <u>www.cosmoshealthinc.com</u></a>,<a href="https://www.globenewswire.com/Tracker?data=m_tSLsfiv_LmGcZk6TMqubdSIK_PRIXrzFbA_SmkYunwz5uhi-lIaQ5mBPrxk987tfrEdeEAMoBBOJpxPXhaoXRLqxFgQCyqz4st5X3Z2TI=" rel="nofollow" target="_blank"> <u>www.skypremiumlife.com</u></a>,<a href="https://www.globenewswire.com/Tracker?data=m_tSLsfiv_LmGcZk6TMquQLOjgB6sWzC1Bnm3fX8zJaFlyK4wX079cltnL8bOX4uifVpsIja7lQ3x5xOaK4i9g==" rel="nofollow" target="_blank"> <u>www.cana.gr</u></a>,<a href="https://www.globenewswire.com/Tracker?data=m_tSLsfiv_LmGcZk6TMquWbBYHDZJHussermV_TCNZKIh_ozu3BHs72Of7d4dQp2hOZ1hGxa8wf1euZ_j3lF_IHpFLgl47s6dKFXUqBCYDY=" rel="nofollow" target="_blank"> <u>www.zipdoctor.co</u></a>, <a href="https://www.globenewswire.com/Tracker?data=s9FuJ_9t6EaPsUxkIOA9lFemfbgAON3t0VCI_TUahOqKQ7yVxWXy8EV80GWFCjY-046RaXGCEqaWSLeiT_tNlWDv1ipOlGB7SHKCjA32Acc=" rel="nofollow" target="_blank"><u>www.cloudscreen.gr</u></a>, as well as<a href="https://www.globenewswire.com/Tracker?data=U7BQWZyWy9V8dNYH9lcEmFvbyf6KlxbnEi7-iQKzGZlbgBWmcWXU8LmlfyxTLtbs-ZPCCwHe_gNMBYCHmQL5kqNjnsAJTPMYjBm38ssZtDASgZBkH2wRzK-rKN-KsgAQ" rel="nofollow" target="_blank"> <u>LinkedIn</u></a> and<a href="https://www.globenewswire.com/Tracker?data=cMbOFLmat-zZR4P2ZiQYiqsCQr30S6WObpBiUvSEcJ7xoQVx10AiH3_NL--Aia94c1hQqnwsAJIWHiNA9miFBFcCA5gLUsfwhU7EqD5FkE0=" rel="nofollow" target="_blank"> <u>X</u></a>.</p>  <p align="justify"><strong>Forward-Looking Statements</strong><br></br>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (<a href="https://www.globenewswire.com/Tracker?data=HUq8G87BNlYRqTXWKhiMUQa6lnzgRUFY6jldVxNYyyXWIGtGjpdvy1FLeKv6M8s9pm-fLFwQ9yWcvgq5L5s7DQ==" rel="nofollow" target="_blank"><u>www.sec.gov</u></a>). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.</p>  <p align="justify"><strong>Investor Relations Contact:</strong><br></br>BDG Communications<br></br><a href="https://www.globenewswire.com/Tracker?data=MUgx3PypU1cOgnwq_oYR5FLoP3kIrG1HIo-_mCMuno-8cSLPo0RSpic1OfvbJHr_tvbL7NCGGLoOMSHt1l3l02i5xetZ9QCOU_8iKfVtsXGz2nJ4GkToPr308JAtCyhO" rel="nofollow" target="_blank">cosm@bdgcommunications.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0ODcwOSM3NjY2NzQ1IzIyOTgwOTQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NTgyNDIwYTUtMGUxOC00YjYzLTljMjYtOWVkNDU1YTg4ZGJjLTEzMDk2NDQtMjAyNi0wNi0xNy1lbg==/tiny/Cosmos-Health-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4"><img src="https://ml.globenewswire.com/media/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4/small/cosmos-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Cosmos Health announced its entry into the global beauty and personal care market with a premium collagen-based skincare line. US direct-to-consumer sales are already live, with plans to scale globally through a multi-brand strategy. The initiative aims to diversify into higher-margin categories and capitalize on a large, growing skincare market.

Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News